Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
31 hedge funds and large institutions have $2.2M invested in Nymox Pharmaceutical Corp in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
79% more call options, than puts
Call options by funds: $240K | Put options by funds: $134K
28% more capital invested
Capital invested by funds: $1.72M → $2.2M (+$482K)
11% more funds holding
Funds holding: 28 → 31 (+3)
0.09% less ownership
Funds ownership: 1.4% → 1.3% (-0.09%)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$154K |
| 2 |
N
Natixis
Paris,
France
|
+$43.2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.9K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$11.3K |
| 5 |
Walleye Trading
New York
|
+$9.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$168K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$89.8K |
| 3 |
WP
WMS Partners
Towson,
Maryland
|
-$53K |
| 4 |
AIG
American International Group
New York
|
-$25K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$13.7K |
NYMX Hedge Fund Activity: Q2 2016 in Review
31 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2016, worth a combined $2.2M — up 28% from $1.72M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NYMX positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $154K. The largest seller was GSA Capital Partners, cutting an estimated $168K.
- 31 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2016, up from 28 in Q1 2016.
- Funds reported $2.2M of Nymox Pharmaceutical Corp stock for Q2 2016, up 28% quarter-over-quarter.
- 6 funds opened new Nymox Pharmaceutical Corp positions in Q2 2016 and 3 closed out, a net change of +3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $154K added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2016 was GSA Capital Partners, an estimated $168K sold.
Based on aggregated 13F filings for Q2 2016.